2024-03-29T00:45:09Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/88752022-07-06T13:31:59Zcom_20.500.12105_2174com_20.500.12105_2051com_20.500.12105_2173col_20.500.12105_2175
00925njm 22002777a 4500
dc
Martínez-Iglesias, Olaia
author
Olmeda, David
author
Alonso-Merino, Elvira
author
Gómez-Rey, Sara
author
González-López, Ana M
author
Luengo, Enrique
author
Soengas, MS
author
Palacios, José
author
Regadera, Javier
author
Aranda, Ana
author
2016-11-29
Vascular Endotelial Growth Factors C and D (VEGF-C and VEGF-D) are crucial regulators of lymphangiogenesis, a main event in the metastatic spread of breast cancer tumors. Although inhibition of lymphangiogenic gene expression might be a useful therapeutic strategy to restrict the progression of cancer, the factors involved in the transcriptional repression of these genes are still unknown. We have previously shown that Nuclear Receptor Corepressor 1 (NCoR) and the thyroid hormone receptor β1 (TRβ) inhibit tumor invasion. Here we show that these molecules repress VEGF-C and VEGF-D gene transcription in breast cancer cells, reducing lymphatic vessel density and sentinel lymph node invasion in tumor xenografts. The clinical significance of these results is stressed by the finding that NCoR and TRβ transcripts correlate negatively with those of the lymphangiogenic genes and the lymphatic vessel marker LYVE-1 in human breast tumors. Our results point to the use of NCoR and TRβ as potential biomarkers for diagnosis or prognosis in breast cancer and suggest that further studies of these molecules as potential targets for anti-lymphangiogenic therapy are warranted.
Oncotarget. 2016;7 (48): 78971-78984 .
1949-2553
http://hdl.handle.net/20.500.12105/8875
27806339
10.18632/oncotarget.12978
1949-2553
Oncotarget
VEGFs
Breast cancer
Lymphangiogenesis
Nuclear receptor corepressor 1
Thyroid hormone receptor beta 1
The nuclear corepressor 1 and the thyroid hormone receptor β suppress breast tumor lymphangiogenesis